Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to explore if "individualized repetitive Transcranial Magnetic Stimulation (TMS)" works to improve symptoms in adults with Irritable Bowel Syndrome (IBS). It also aims to learn how this treatment works (by looking at links between the brain, gut, and gut bacteria) and if tests like brain scans or gut bacteria checks can show if the treatment will work for a person. The main questions it aims to answer are:
Will individualized TMS improve IBS symptoms (like stomach pain or discomfort) and affect the links between the brain, gut, and gut bacteria? Can brain scan results (from multimodal Magnetic Resonance Imaging, MRI) and gut bacteria checks (from high-throughput sequencing) predict how well a person responds to TMS?
Participants will be adults aged 18-59 who:
Meet the Rome Ⅳ criteria for IBS (a standard way to diagnose IBS); Have stopped taking IBS-related medicines for more than 2 weeks; Do NOT have MRI or TMS contraindications (like metal implants in the body, mental illness, pregnancy, or serious illnesses requiring hospital stays).
Participants will:
Receive 10 TMS sessions (5 times a week, for 2 weeks total) - TMS is a non-invasive treatment that uses gentle magnetic pulses on the scalp;
Before the first TMS session, and again after the 10th session:
Fill out surveys to rate IBS symptoms; Have an MRI scan (painless, takes about 60 minutes) to look at brain activity; Provide a small stool sample to check gut bacteria.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Individualized TMS Intervention | Experimental | Participants in this group receive the individualized transcranial magnetic stimulation (TMS) intervention. |
|
| Sham TMS Intervention | Sham Comparator | Participants in this group receive the sham TMS intervention (for blinding purposes). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Individualized TMS Intervention | Device | This individualized transcranial magnetic stimulation (TMS) intervention distinguishes itself from conventional fixed-target TMS by using resting-state fMRI functional connectivity to determine the personalized left dorsolateral prefrontal cortex (DLPFC) target. It uses a Magstim TMS system (infrared optical navigation) for precise positioning. Stimulation intensity is 90% of the individual's resting motor threshold (RMT; MEPs >50μV in ≥5/10 stimulations), delivered via the iTBS paradigm (3 pulses/burst [50Hz], 5Hz burst repetition, 2s stimulation/8s rest, 3 cycles/1800 pulses per session). This personalized targeting design enhances precision, setting it apart from non-individualized TMS in other studies. |
| Measure | Description | Time Frame |
|---|---|---|
| Irritable Bowel Syndrome Symptom Severity Rating Scale (IBS-SSS) | Assessment of the severity of irritable bowel syndrome symptoms (including abdominal pain, bloating, diarrhea/constipation, and impact on daily life) using the IBS-SSS. Scale Details: Minimum value: 0 points; Maximum value: 500 points; Score interpretation: Higher scores indicate more severe IBS symptoms. | Baseline (within 1 week before the first TMS session), post-treatment (within 24 hours after the 10th TMS session), 1 month after treatment (±7 days), 3 months after treatment (±7 days) |
| Measure | Description | Time Frame |
|---|---|---|
| Fecal microbiota composition | Analysis of the composition and diversity of fecal microbiota (including phylum, genus, and species levels) using high-throughput sequencing of 16S rRNA genes. | Baseline (within 1 week before the first TMS session), post-treatment (within 24 hours after the 10th TMS session) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The affiliated hospital of Hangzhou Normal University | Hangzhou | Zhejiang | 310015 | China |
Not provided
This study adopts a parallel group design, with participants randomly assigned to either the individualized TMS intervention group or the sham-TMS control group. The two groups are compared simultaneously to evaluate the efficacy and safety of the intervention.
Not provided
Not provided
Not provided
|
| Sham TMS Intervention | Device | This sham TMS intervention is designed to maintain double-blinding: it uses the same equipment (Magstim infrared navigation TMS system), procedures (individual RMT measurement, personalized left DLPFC target positioning), iTBS paradigm (3 pulses/burst [50Hz], 5Hz repetition, 2s/8s cycle, 1800 pulses/session) and duration (20min core/40min total per session, 10 total sessions) as the individualized TMS in this study. Its only distinction (from the experimental intervention) is the 90° coil orientation (directing magnetic field away from the scalp, no effective cortical stimulation). |
|
| Fecal Metabolic Profile |
Detection of fecal metabolic metabolites (including amino acids, short-chain fatty acids, and bile acids) using liquid chromatography-mass spectrometry (LC-MS) based metabolomics. |
| Baseline (within 1 week before the first TMS session), post-treatment (within 24 hours after the 10th TMS session) |
| Visual Analogue Scale (VAS) for Pain | Assessment of the degree of abdominal pain in participants using a 10-point visual analog scale. Scale Details: Minimum value: 0 points (no pain); Maximum value: 10 points (most severe pain imaginable). Score interpretation: Higher scores indicate more severe abdominal pain. | Baseline (within 1 week before the first TMS session), post-treatment (within 24 hours after the 10th TMS session), 1 month after treatment (±7 days), 3 months after treatment (±7 days) |
| Short-Form McGill Pain Questionnaire (SF-MPQ) | Evaluates multi-dimensional characteristics of abdominal pain in participants, including pain intensity (assessed via visual analog scale and numerical rating scale) and pain quality (e.g., stabbing, bloating, cramping). Scale Details: Minimum value: 0 points; Maximum value: 45 points; Score interpretation: Higher scores indicate more severe and distressing abdominal pain. | Baseline (within 1 week before the first TMS session), post-treatment (within 24 hours after the 10th TMS session), 1 month after treatment (±7 days), 3 months after treatment (±7 days) |
| Irritable Bowel Syndrome Quality of Life Scale (IBS-QOL) | Assesses the impact of irritable bowel syndrome on participants' quality of life, covering dimensions such as symptom distress, emotional function, social function, and daily activity limitation. Scale Details: Minimum value: 0 points; Maximum value: 100 points; Score interpretation: Higher scores indicate better quality of life (less impact from IBS symptoms). | Baseline (within 1 week before the first TMS session), post-treatment (within 24 hours after the 10th TMS session), 1 month after treatment (±7 days), 3 months after treatment (±7 days) |
| 17 items-Hamilton Depression Rating Scale (HAMD-17) | Assessment of the severity of depressive symptoms in participants using the 17-item Hamilton Depression Rating Scale. Scale Details: Minimum value: 0 points; Maximum value: 54 points; Score interpretation: Higher scores indicate more severe depressive symptoms. | Baseline (within 1 week before the first TMS session), post-treatment (within 24 hours after the 10th TMS session), 1 month after treatment (±7 days), 3 months after treatment (±7 days) |
| 14 items-Hamilton Anxiety Rating Scale (HAMA-14) | Assesses the severity of anxiety symptoms in participants, covering both psychological anxiety dimensions (e.g., tension, fear, restlessness) and somatic anxiety dimensions (e.g., palpitations, muscle soreness, gastrointestinal discomfort). Scale Details: Minimum value: 0 points; Maximum value: 56 points; Score interpretation: Higher scores indicate more severe anxiety symptoms. | Baseline (within 1 week before the first TMS session), post-treatment (within 24 hours after the 10th TMS session), 1 month after treatment (±7 days), 3 months after treatment (±7 days) |
| Brain Function Features (Multimodal MRI) | Assessment of brain functional indicators covering multiple dimensions of neural activity and circuit organization:
The above are representative indicators; other relevant brain functional metrics may be included as needed. | Baseline (within 1 week before the first TMS session), post-treatment (within 24 hours after the 10th TMS session), 1 month after treatment (±7 days), 3 months after treatment (±7 days) |
| Brain Structure Features (Multimodal MRI) | Assessment of brain structural indicators including gray matter volume (measured by voxel-based morphometry) and white matter integrity (measured by fractional anisotropy via diffusion tensor imaging). | Baseline (within 1 week before the first TMS session), post-treatment (within 24 hours after the 10th TMS session), 1 month after treatment (±7 days), 3 months after treatment (±7 days) |
| ID | Term |
|---|---|
| D043183 | Irritable Bowel Syndrome |
| D010146 | Pain |
| D003866 | Depressive Disorder |
| D008224 | Lymphoma, Follicular |
| ID | Term |
|---|---|
| D003109 | Colonic Diseases, Functional |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided